Simya VC, established by 212, has invested $500,000 in reprai, an AI-driven startup focused on transforming pharmaceutical engagement across Europe and the US.
Simya VC targets AI-driven healthcare solutions
As part of its mission to support early-stage companies, Simya VC announced a $500,000 investment in reprai, a startup using artificial intelligence to reshape how pharmaceutical companies interact with healthcare professionals. The venture capital fund, created by 212, continues to channel resources into businesses that demonstrate potential for scalability in international markets.
Reducing costs and enhancing efficiency
Selma Bahcivanoglu, Managing Partner at Simya VC, explained that the pharmaceutical industry is shifting as traditional sales channels lose ground to digital tools. She highlighted that in the United States, a doctor–representative meeting typically costs around $500, but with reprai’s solution, this can drop to under $20. According to Bahcivanoglu, this dramatic reduction in cost underscores the efficiency gains and scalability potential of the platform. She also noted that the founding team’s combined expertise—led by Didem Aral, Ozhan Ozturk, Cihan Sahin, and Charles Randall—has helped the company secure a strong product-market fit in its early phase.
Reprai’s international growth strategy
Reprai is developing scalable engagement models that enable pharmaceutical firms to optimize marketing channels and improve access to healthcare professionals through AI-based tools. The company intends to use the new funding to expand its workforce, enhance its technology, and increase market presence in both Europe and the United States.
Building toward global industry influence
Co-Founder and CEO Didem Aral said the company was built to drive AI adoption in pharmaceutical marketing, with an early focus on strategic regions such as Europe and the US. She added that the latest investment would allow reprai not only to grow its customer base but also to pursue its ambition of becoming a global player capable of influencing industry standards.
The $500,000 investment signals a step forward for Simya VC in backing health-tech ventures, while offering reprai the resources to accelerate its expansion and strengthen its role in the digital transformation of pharmaceutical marketing worldwide.
Related
